Drug
3-Iodobenzylguanidine clinical trials
Also written 131I-MIBG.
Keep track of what changes. Save the 3-Iodobenzylguanidine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
- MIBG
- 2
Combined with it in one product
Studies by the year they started
15 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 13
David Bushnell (2) · Molecular Insight Pharmaceuticals, Inc. (2) · Mayo Clinic (2) · Nationwide Children's Hospital (1) · Masonic Cancer Center, University of Minnesota (1) · Cancer Research UK (1) · University of California, San Francisco (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Iobenguane sulfate i-123 (2) · Iobenguane I-123 (2) · Cold Contaminant-free Iobenguane I-131 (2) · Edotreotide yttrium y-90 (1) · Fludarabine (1) · Thiotepa (1) · Rituximab (1)
Studies
Open first, then newest update. How each study uses 3-Iodobenzylguanidine is read from its arms, and is right about nine times in ten.
Testing it · 16
- MIBG in Aging and Neurologic DisordersEnrolling by invitationPhase 4Mayo ClinicNCT05514106Written as meta-iodobenzylguanidine (MIBG) (123I)
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or ParagangliomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT00107289Written as iobenguane I 131
- MIBG for Refractory Neuroblastoma and PheochromocytomaCompletedNot applicableMasonic Cancer Center, University of MinnesotaNCT01850888Written as 131 I-Metaiodobenzylguanidine (131I-MIBG)
- MIBG Therapy for Patients With MIBG Avid TumorsActive, not recruitingPhase 2Nationwide Children's HospitalNCT02378428Written as MIBG
- A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine TumorsWithdrawnPhase 1/2David BushnellNCT04614766Written as Azedra
- Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine TumorsActive, not recruitingEarly Phase 1David BushnellNCT03044977Written as 131I-MIBG
- A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma SubjectsStatus unknownPhase 2Jubilant DraxImage Inc.NCT03561259Written as 131I-MIBG
- A Phase I/II Study of [124I]mIBG PET/CT in NeuroblastomaCompletedPhase 1/2Cancer Research UKNCT02043899Written as [124I]meta-Iodobenzylguanidine
- Haploidentical Stem Cell Transplantation in NeuroblastomaStatus unknownEarly Phase 1Lund University HospitalNCT00790413Written as iodine I 131 metaiodobenzylguanidine
- High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed NeuroblastomaCompletedPhase 1University of California, San FranciscoNCT01313936Written as Metaiodobenzylguanidine (MIBG)
- High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine TumorsCompletedPhase 3M.D. Anderson Cancer CenterNCT00037869Written as I-131 Metaiodobenzylguanidine
- 123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT SystemCompletedPhase 4Timothy M. BatemanNCT01868841Written as AdreView
- N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk NeuroblastomaCompletedPhase 2Molecular Insight Pharmaceuticals, Inc.NCT00659984Written as UltratraceTM Iobenguane I 131 Imaging
- Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) ImagingTerminatedPhase 1Mayo ClinicNCT01522378Written as 123 iodine metaiodobenzylguanidine
- Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/ParagangliomaCompletedPhase 1/2Molecular Insight Pharmaceuticals, Inc.NCT00458952Written as Ultratrace Iobenguane (MIBG) I 131
- CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II StudyStatus unknownPhase 2National Center for Research Resources (NCRR)NCT00013806Written as 131I-MIBG
Given in every arm · 1 — 3-Iodobenzylguanidine is usual care beside what is tested
As the comparator · 1 — what is tested is compared with 3-Iodobenzylguanidine
Codes
What other systems call 3-Iodobenzylguanidine · ClinicalTrials.gg INT008719
- MeSH (NLM) D0197973-IodobenzylguanidineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 35MRW7B4ADIOBENGUANEConfirmed FDA, NLM
- RxNorm 14448One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D019797 | 3-Iodobenzylguanidine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 35MRW7B4AD | IOBENGUANE | Confirmed FDA, NLM |
| RxNorm | 14448 | — | One source FDA |
Also registered as iobenguane i-131 (UNII Q461L7AK4R · RxNorm 2053281).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.